Herasight key facts
- Operator of an advanced embryo screening company intended for prospective parents to assess genetic risk and trait likelihood before implantation.
- Notable investors include Draper Associates, NZVC, Compagnie d'Investissements et de Gestion Privée, LongGame.
- Status: Privately Held (backing).
Who backs Herasight
4- ·Watch Herasight: the Monday email on marks, rounds and moves
Herasight funding rounds
No funding rounds for Herasight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Herasight investors
4 investors are on record for Herasight, including Draper Associates, NZVC, Compagnie d'Investissements et de Gestion Privée and LongGame.
About Herasight
Operator of an advanced embryo screening company intended for prospective parents to assess genetic risk and trait likelihood before implantation. The company's platform integrates ultra-low pass sequencing, family medical history, ancestry-aware polygenic scoring, embryo simulation, and disease trait risk stratification, enabling fertility clinics and IVF patients to make data-driven embryo selection decisions that account for both monogenic and complex condition prediction across diverse genetic backgrounds.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Website
- herasight.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Herasight doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.